Immunotherapy based on bispecific T‐cell engager with hIgG 1 Fc sequence as a new therapeutic strategy in multiple myeloma

Autor: Jinle Tang, Gangli An, Dan Chen, Lin Yang, Xingding Zhang, Yunhui Zong, Sisi Ye, Jianxuan Zou, Huimin Meng
Rok vydání: 2015
Předmět:
Antigens
Differentiation
T-Lymphocyte
Cancer Research
Bispecific antibody
CD3 Complex
medicine.drug_class
T-Lymphocytes
medicine.medical_treatment
T cell
Molecular Sequence Data
T cells
chemical and pharmacologic phenomena
Mice
SCID
Biology
Monoclonal antibody
law.invention
Antigens
CD
law
Cell Line
Tumor
Antibodies
Bispecific
medicine
Animals
Humans
Lectins
C-Type
Amino Acid Sequence
Multiple myeloma
natural killer cells
Receptors
IgG
Interleukin-2 Receptor alpha Subunit
Original Articles
General Medicine
Immunotherapy
respiratory system
medicine.disease
Xenograft Model Antitumor Assays
Isotype
Molecular biology
Recombinant Proteins
multiple myeloma
Killer Cells
Natural
medicine.anatomical_structure
Oncology
Immunoglobulin G
Recombinant DNA
biology.protein
Syndecan-1
Antibody
Bispecific antibodies
Single-Chain Antibodies
Zdroj: Cancer Science
ISSN: 1349-7006
1347-9032
Popis: Bispecific antibodies play an important role in immunotherapy. They have received intense interest from pharmaceutical enterprises. The first antibody drug, OKT3 (muromonab-CD3), showed great performance in clinical treatment. We have successfully developed a single-chain variable fragment (ScFv) combination of anti-CD3 ScFv and anti-CD138 ScFv with the hIgG1 Fc (hIgFc) sequence. The novel bispecific T-cell engager (BiTE) with an additional hIgFc (BiTE-hIgFc, STL001) can target T cells, natural killer cells, and multiple myeloma cells (RPMI-8226 or U266). In addition, BiTE-hIgFc (STL001) has nanomolar-level affinity to recombinant human CD138 protein and shows more potent antitumor activity against RPMI-8226 cells than that of separate aCD3-ScFv-hIgFc and aCD138-ScFv-hIgFc, or the isotype mAb in vitro or in vivo.
Databáze: OpenAIRE
Externí odkaz: